Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 385

1.

Quality Monitoring of a FIT-Based Colorectal Cancer Screening Program.

Toes-Zoutendijk E, Bonfrer JMG, Ramakers C, Thelen M, Spaander MCW, Dekker E, van der Meulen MP, Buskermolen M, van Vuuren AJ, Kuipers EJ, van Kemenade FJ, van Velthuysen MF, Thomeer MGJ, van Veldhuizen H, van Ballegooijen M, de Koning HJ, van Leerdam ME, Lansdorp-Vogelaar I.

Clin Chem. 2019 Jan 16. pii: clinchem.2018.294041. doi: 10.1373/clinchem.2018.294041. [Epub ahead of print]

PMID:
30651228
2.

Persisting new nodules in incidence rounds of the NELSON CT lung cancer screening study.

Walter JE, Heuvelmans MA, Ten Haaf K, Vliegenthart R, van der Aalst CM, Yousaf-Khan U, van Ooijen PMA, Nackaerts K, Groen HJM, De Bock GH, de Koning HJ, Oudkerk M.

Thorax. 2019 Mar;74(3):247-253. doi: 10.1136/thoraxjnl-2018-212152. Epub 2018 Dec 27.

PMID:
30591535
3.

Relationship between the number of new nodules and lung cancer probability in incidence screening rounds of CT lung cancer screening: The NELSON study.

Walter JE, Heuvelmans MA, de Bock GH, Yousaf-Khan U, Groen HJM, van der Aalst CM, Nackaerts K, van Ooijen PMA, de Koning HJ, Vliegenthart R, Oudkerk M.

Lung Cancer. 2018 Nov;125:103-108. doi: 10.1016/j.lungcan.2018.05.007. Epub 2018 May 14.

4.

A choice experiment to identify the most important elements of a successful cancer screening program according to those who research and manage such programs.

Priaulx J, Csanádi M, de Koning HJ, McKee M.

Int J Health Plann Manage. 2018 Oct 31. doi: 10.1002/hpm.2697. [Epub ahead of print]

PMID:
30378696
5.

Modeling in Colorectal Cancer Screening: Assessing External and Predictive Validity of MISCAN-Colon Microsimulation Model Using NORCCAP Trial Results.

Buskermolen M, Gini A, Naber SK, Toes-Zoutendijk E, de Koning HJ, Lansdorp-Vogelaar I.

Med Decis Making. 2018 Nov;38(8):917-929. doi: 10.1177/0272989X18806497. Epub 2018 Oct 20.

PMID:
30343626
6.

A health systems approach to identifying barriers to breast cancer screening programmes. Methodology and application in six European countries.

Turnbull E, Priaulx J, van Ravesteyn NT, Heinävaara S, Siljander I, Senore C, Segnan N, Vokó Z, Hagymásy J, Jarm K, Veerus P, de Koning HJ, McKee M.

Health Policy. 2018 Nov;122(11):1198-1205. doi: 10.1016/j.healthpol.2018.08.003. Epub 2018 Aug 24.

PMID:
30195444
7.

The health impact of human papillomavirus vaccination in the situation of primary human papillomavirus screening: A mathematical modeling study.

Matthijsse SM, Naber SK, Hontelez JAC, Bakker R, van Ballegooijen M, Lansdorp-Vogelaar I, de Kok IMCM, de Koning HJ, van Rosmalen J, de Vlas SJ.

PLoS One. 2018 Sep 4;13(9):e0202924. doi: 10.1371/journal.pone.0202924. eCollection 2018.

8.

Identifying the barriers to effective breast, cervical and colorectal cancer screening in thirty one European countries using the Barriers to Effective Screening Tool (BEST).

Priaulx J, de Koning HJ, de Kok IMCM, Széles G, McKee M.

Health Policy. 2018 Nov;122(11):1190-1197. doi: 10.1016/j.healthpol.2018.08.004. Epub 2018 Aug 27.

PMID:
30177278
9.

Results of a health systems approach to identify barriers to population-based cervical and colorectal cancer screening programmes in six European countries.

Turnbull E, Priaulx J, de Kok IMCM, Lansdorp-Vogelaar I, Anttila A, Sarkeala T, Senore C, Segnan N, Csanádi M, Pitter J, Novak Mlakar D, Ivanus U, Veerus P, de Koning HJ, McKee M.

Health Policy. 2018 Nov;122(11):1206-1211. doi: 10.1016/j.healthpol.2018.08.005. Epub 2018 Aug 24.

PMID:
30170757
10.

Cost-effectiveness of surveillance schedules in older adults with non-muscle-invasive bladder cancer.

Heijnsdijk EAM, Nieboer D, Garg T, Lansdorp-Vogelaar I, de Koning HJ, Nielsen ME.

BJU Int. 2019 Feb;123(2):307-312. doi: 10.1111/bju.14502. Epub 2018 Aug 27.

PMID:
30066439
11.

Cost-effectiveness of low-dose CT screening for lung cancer in a European country with high prevalence of smoking-A modelling study.

Tomonaga Y, Ten Haaf K, Frauenfelder T, Kohler M, Kouyos RD, Shilaih M, Lorez M, de Koning HJ, Schwenkglenks M, Puhan MA.

Lung Cancer. 2018 Jul;121:61-69. doi: 10.1016/j.lungcan.2018.05.008. Epub 2018 May 26.

PMID:
29858029
12.

New Subsolid Pulmonary Nodules in Lung Cancer Screening: The NELSON Trial.

Walter JE, Heuvelmans MA, Yousaf-Khan U, Dorrius MD, Thunnissen E, Schermann A, Groen HJM, van der Aalst CM, Nackaerts K, Vliegenthart R, de Koning HJ, Oudkerk M.

J Thorac Oncol. 2018 Sep;13(9):1410-1414. doi: 10.1016/j.jtho.2018.05.006. Epub 2018 Jul 12.

PMID:
29775805
13.

Reasons for (non)participation in supplemental population-based MRI breast screening for women with extremely dense breasts.

de Lange SV, Bakker MF, Monninkhof EM, Peeters PHM, de Koekkoek-Doll PK, Mann RM, Rutten MJCM, Bisschops RHC, Veltman J, Duvivier KM, Lobbes MBI, de Koning HJ, Karssemeijer N, Pijnappel RM, Veldhuis WB, van Gils CH.

Clin Radiol. 2018 Aug;73(8):759.e1-759.e9. doi: 10.1016/j.crad.2018.04.002. Epub 2018 Jun 18.

PMID:
29759590
14.

Introduction to the Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Models.

Alagoz O, Berry DA, de Koning HJ, Feuer EJ, Lee SJ, Plevritis SK, Schechter CB, Stout NK, Trentham-Dietz A, Mandelblatt JS; CISNET Breast Cancer Working Group members.

Med Decis Making. 2018 Apr;38(1_suppl):3S-8S. doi: 10.1177/0272989X17737507.

PMID:
29554472
15.

Comparing CISNET Breast Cancer Models Using the Maximum Clinical Incidence Reduction Methodology.

van den Broek JJ, van Ravesteyn NT, Mandelblatt JS, Cevik M, Schechter CB, Lee SJ, Huang H, Li Y, Munoz DF, Plevritis SK, de Koning HJ, Stout NK, van Ballegooijen M.

Med Decis Making. 2018 Apr;38(1_suppl):112S-125S. doi: 10.1177/0272989X17743244.

PMID:
29554471
16.

Simulating the Impact of Risk-Based Screening and Treatment on Breast Cancer Outcomes with MISCAN-Fadia.

van den Broek JJ, van Ravesteyn NT, Heijnsdijk EA, de Koning HJ.

Med Decis Making. 2018 Apr;38(1_suppl):54S-65S. doi: 10.1177/0272989X17711928.

PMID:
29554469
17.

Comparing CISNET Breast Cancer Incidence and Mortality Predictions to Observed Clinical Trial Results of Mammography Screening from Ages 40 to 49.

van den Broek JJ, van Ravesteyn NT, Mandelblatt JS, Huang H, Ergun MA, Burnside ES, Xu C, Li Y, Alagoz O, Lee SJ, Stout NK, Song J, Trentham-Dietz A, Plevritis SK, Moss SM, de Koning HJ.

Med Decis Making. 2018 Apr;38(1_suppl):140S-150S. doi: 10.1177/0272989X17718168.

PMID:
29554468
18.

Modeling Ductal Carcinoma In Situ (DCIS): An Overview of CISNET Model Approaches.

van Ravesteyn NT, van den Broek JJ, Li X, Weedon-Fekjær H, Schechter CB, Alagoz O, Huang X, Weaver DL, Burnside ES, Punglia RS, de Koning HJ, Lee SJ.

Med Decis Making. 2018 Apr;38(1_suppl):126S-139S. doi: 10.1177/0272989X17729358.

PMID:
29554463
19.

High-pitch versus sequential mode for coronary calcium in individuals with a high heart rate: Potential for dose reduction.

Vonder M, Vliegenthart R, Kaatee MA, van der Aalst CM, van Ooijen PMA, de Bock GH, Gratama JW, Kuijpers D, de Koning HJ, Oudkerk M.

J Cardiovasc Comput Tomogr. 2018 Jul - Aug;12(4):298-304. doi: 10.1016/j.jcct.2018.02.005. Epub 2018 Mar 1.

PMID:
29551663
20.

Detection and interval cancer rates during the transition from screen-film to digital mammography in population-based screening.

Sankatsing VDV, Fracheboud J, de Munck L, Broeders MJM, van Ravesteyn NT, Heijnsdijk EAM, Verbeek ALM, Otten JDM, Pijnappel RM, Siesling S, de Koning HJ; National Evaluation Team for Breast cancer screening, NETB.

BMC Cancer. 2018 Mar 5;18(1):256. doi: 10.1186/s12885-018-4122-2.

21.

Clinically detected non-aggressive lung cancers: implications for overdiagnosis and overtreatment in lung cancer screening.

Ten Haaf K, van der Aalst CM, de Koning HJ.

Thorax. 2018 May;73(5):407-408. doi: 10.1136/thoraxjnl-2017-211149. Epub 2018 Feb 9. No abstract available.

PMID:
29440512
22.

Using Collaborative Simulation Modeling to Develop a Web-Based Tool to Support Policy-Level Decision Making About Breast Cancer Screening Initiation Age.

Burnside ES, Lee SJ, Bennette C, Near AM, Alagoz O, Huang H, van den Broek JJ, Kim JY, Ergun MA, van Ravesteyn NT, Stout NK, de Koning HJ, Mandelblatt JS.

MDM Policy Pract. 2017 Jul;2. doi: 10.1177/2381468317717982. Epub 2017 Jul 8.

23.

Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012.

Plevritis SK, Munoz D, Kurian AW, Stout NK, Alagoz O, Near AM, Lee SJ, van den Broek JJ, Huang X, Schechter CB, Sprague BL, Song J, de Koning HJ, Trentham-Dietz A, van Ravesteyn NT, Gangnon R, Chandler Y, Li Y, Xu C, Ergun MA, Huang H, Berry DA, Mandelblatt JS.

JAMA. 2018 Jan 9;319(2):154-164. doi: 10.1001/jama.2017.19130. Erratum in: JAMA. 2018 Feb 20;319(7):724.

24.

Distinguishing between CISNET model results versus CISNET models.

Berry DA, de Koning HJ, Lee SJ, Mandelblatt JS, Plevritis SK, Schechter CB, Stout NK, Trentham-Dietz A; CISNET Breast Working Group Principal Investigators.

Cancer. 2018 Mar 1;124(5):1083-1084. doi: 10.1002/cncr.31150. Epub 2017 Dec 26. No abstract available.

PMID:
29278430
25.

Comparative effectiveness of prostate cancer screening between the ages of 55 and 69 years followed by active surveillance.

de Carvalho TM, Heijnsdijk EAM, de Koning HJ.

Cancer. 2018 Feb 1;124(3):507-513. doi: 10.1002/cncr.31141. Epub 2017 Dec 12.

26.

The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.

de Koning HJ, Gulati R, Moss SM, Hugosson J, Pinsky PF, Berg CD, Auvinen A, Andriole GL, Roobol MJ, Crawford ED, Nelen V, Kwiatkowski M, Zappa M, Luján M, Villers A, de Carvalho TM, Feuer EJ, Tsodikov A, Mariotto AB, Heijnsdijk EAM, Etzioni R.

Cancer. 2018 Mar 15;124(6):1197-1206. doi: 10.1002/cncr.31178. Epub 2017 Dec 6.

PMID:
29211316
27.

Re: Think before you leap.

Han SS, Ten Haaf K, Hazelton WD, Jeon J, Meza R, Kong CY, Feuer EJ, de Koning HJ, Plevritis SK.

Int J Cancer. 2018 Apr 1;142(7):1507-1509. doi: 10.1002/ijc.31183. Epub 2017 Dec 28. No abstract available.

PMID:
29194597
28.

Disagreement of diameter and volume measurements for pulmonary nodule size estimation in CT lung cancer screening.

Heuvelmans MA, Walter JE, Vliegenthart R, van Ooijen PMA, De Bock GH, de Koning HJ, Oudkerk M.

Thorax. 2018 Aug;73(8):779-781. doi: 10.1136/thoraxjnl-2017-210770. Epub 2017 Oct 22.

PMID:
29056601
29.

Lung cancer screening and its continuous risk assessment.

de Koning HJ.

Lancet Oncol. 2017 Nov;18(11):1434-1436. doi: 10.1016/S1470-2045(17)30730-1. Epub 2017 Oct 18. No abstract available.

PMID:
29055737
30.

Summary statement on screening for prostate cancer in Europe.

Heijnsdijk EAM, Bangma CH, Borràs JM, de Carvalho TM, Castells X, Eklund M, Espinàs JA, Graefen M, Grönberg H, Lansdorp-Vogelaar I, Leeuwen PJV, Nelen V, Recker F, Roobol MJ, Vandenbulcke P, de Koning HJ.

Int J Cancer. 2018 Feb 15;142(4):741-746. doi: 10.1002/ijc.31102. Epub 2017 Oct 25.

31.

Influence of lung nodule margin on volume- and diameter-based reader variability in CT lung cancer screening.

Han D, Heuvelmans MA, Vliegenthart R, Rook M, Dorrius MD, de Jonge GJ, Walter JE, van Ooijen PMA, de Koning HJ, Oudkerk M.

Br J Radiol. 2018 Oct;91(1090):20170405. doi: 10.1259/bjr.20170405. Epub 2017 Nov 8.

PMID:
28972803
32.

Accuracy of screening women at familial risk of breast cancer without a known gene mutation: Individual patient data meta-analysis.

Phi XA, Houssami N, Hooning MJ, Riedl CC, Leach MO, Sardanelli F, Warner E, Trop I, Saadatmand S, Tilanus-Linthorst MMA, Helbich TH, van den Heuvel ER, de Koning HJ, Obdeijn IM, de Bock GH.

Eur J Cancer. 2017 Nov;85:31-38. doi: 10.1016/j.ejca.2017.07.055. Review.

PMID:
28886475
33.

Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.

Tsodikov A, Gulati R, Heijnsdijk EAM, Pinsky PF, Moss SM, Qiu S, de Carvalho TM, Hugosson J, Berg CD, Auvinen A, Andriole GL, Roobol MJ, Crawford ED, Nelen V, Kwiatkowski M, Zappa M, Luján M, Villers A, Feuer EJ, de Koning HJ, Mariotto AB, Etzioni R.

Ann Intern Med. 2017 Oct 3;167(7):449-455. doi: 10.7326/M16-2586. Epub 2017 Sep 5.

34.

Coronary Artery Calcium Imaging in the ROBINSCA Trial: Rationale, Design, and Technical Background.

Vonder M, van der Aalst CM, Vliegenthart R, van Ooijen PMA, Kuijpers D, Gratama JW, de Koning HJ, Oudkerk M.

Acad Radiol. 2018 Jan;25(1):118-128. doi: 10.1016/j.acra.2017.07.010. Epub 2017 Aug 23. Review.

PMID:
28843465
35.

Uniform and blinded cause of death verification of the NELSON lung cancer screening participants.

Yousaf-Khan AU, van der Aalst CM, Aerts JGJV, den Bakker MA, de Koning HJ.

Lung Cancer. 2017 Sep;111:131-134. doi: 10.1016/j.lungcan.2017.07.018. Epub 2017 Jul 22.

PMID:
28838383
36.

Evaluation of the colorectal cancer screening Programme in the Basque Country (Spain) and its effectiveness based on the Miscan-colon model.

Idigoras I, Arrospide A, Portillo I, Arana-Arri E, Martínez-Indart L, Mar J, de Koning HJ, Lastra R, Soto-Gordoa M, van der Meulen M, Lansdorp-Vogelaar I.

BMC Public Health. 2017 Aug 1;18(1):78. doi: 10.1186/s12889-017-4639-3. Erratum in: BMC Public Health. 2017 Sep 22;17 (1):736.

37.

The effect of omitting an early population-based vision screen in the Netherlands: A micro-simulation model approach.

Sloot F, Heijnsdijk E, Groenewoud JH, Goudsmit F, Steyerberg EW, de Koning HJ, Simonsz HJ.

J Med Screen. 2017 Sep;24(3):120-126. doi: 10.1177/0969141316670422. Epub 2016 Oct 22.

PMID:
28756763
38.

Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening.

Lansdorp-Vogelaar I, Goede SL, Bosch LJW, Melotte V, Carvalho B, van Engeland M, Meijer GA, de Koning HJ, van Ballegooijen M.

Clin Gastroenterol Hepatol. 2018 Apr;16(4):504-512.e11. doi: 10.1016/j.cgh.2017.07.011. Epub 2017 Jul 18.

PMID:
28733262
39.

Authors' reply to: "Questionable method for estimating the influence of mammography screening on breast cancer mortality in the Netherlands".

Sankatsing VDV, van Ravesteyn NT, Heijnsdijk EAM, de Koning HJ.

Int J Cancer. 2017 Oct 15;141(8):1709-1710. doi: 10.1002/ijc.30873. Epub 2017 Jul 21. No abstract available.

40.

Quantification of growth patterns of screen-detected lung cancers: The NELSON study.

Heuvelmans MA, Vliegenthart R, de Koning HJ, Groen HJM, van Putten MJAM, Yousaf-Khan U, Weenink C, Nackaerts K, de Jong PA, Oudkerk M.

Lung Cancer. 2017 Jun;108:48-54. doi: 10.1016/j.lungcan.2017.02.021. Epub 2017 Mar 1.

41.

Do Men and Women Need to Be Screened Differently with Fecal Immunochemical Testing? A Cost-Effectiveness Analysis.

Meulen MPV, Kapidzic A, Leerdam MEV, van der Steen A, Kuipers EJ, Spaander MCW, de Koning HJ, Hol L, Lansdorp-Vogelaar I.

Cancer Epidemiol Biomarkers Prev. 2017 Aug;26(8):1328-1336. doi: 10.1158/1055-9965.EPI-16-0786. Epub 2017 May 17.

42.

Optimum Management of Pulmonary Nodules.

de Koning HJ, Oudkerk M, Lammers JJ.

Radiology. 2017 Jun;283(3):917-919. doi: 10.1148/radiol.2017160694. No abstract available.

PMID:
28514222
43.

The effect of population-based mammography screening in Dutch municipalities on breast cancer mortality: 20 years of follow-up.

Sankatsing VDV, van Ravesteyn NT, Heijnsdijk EAM, Looman CWN, van Luijt PA, Fracheboud J, den Heeten GJ, Broeders MJM, de Koning HJ.

Int J Cancer. 2017 Aug 15;141(4):671-677. doi: 10.1002/ijc.30754.

44.

Is prostate cancer different in black men? Answers from 3 natural history models.

Tsodikov A, Gulati R, de Carvalho TM, Heijnsdijk EAM, Hunter-Merrill RA, Mariotto AB, de Koning HJ, Etzioni R.

Cancer. 2017 Jun 15;123(12):2312-2319. doi: 10.1002/cncr.30687. Epub 2017 Apr 24.

45.

When should active surveillance for prostate cancer stop if no progression is detected?

de Carvalho TM, Heijnsdijk EAM, de Koning HJ.

Prostate. 2017 Jun;77(9):962-969. doi: 10.1002/pros.23352. Epub 2017 Apr 17.

PMID:
28419541
46.

Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study.

Ten Haaf K, Jeon J, Tammemägi MC, Han SS, Kong CY, Plevritis SK, Feuer EJ, de Koning HJ, Steyerberg EW, Meza R.

PLoS Med. 2017 Apr 4;14(4):e1002277. doi: 10.1371/journal.pmed.1002277. eCollection 2017 Apr.

47.

Bone density loss on computed tomography at 3-year follow-up in current compared to former male smokers.

Pompe E, Bartstra J, Verhaar HJ, de Koning HJ, van der Aalst CM, Oudkerk M, Vliegenthart R, Lammers JJ, de Jong PA, Mohamed Hoesein FAA.

Eur J Radiol. 2017 Apr;89:177-181. doi: 10.1016/j.ejrad.2017.02.011. Epub 2017 Feb 9.

PMID:
28267536
48.

Performance and Cost-Effectiveness of Computed Tomography Lung Cancer Screening Scenarios in a Population-Based Setting: A Microsimulation Modeling Analysis in Ontario, Canada.

Ten Haaf K, Tammemägi MC, Bondy SJ, van der Aalst CM, Gu S, McGregor SE, Nicholas G, de Koning HJ, Paszat LF.

PLoS Med. 2017 Feb 7;14(2):e1002225. doi: 10.1371/journal.pmed.1002225. eCollection 2017 Feb.

49.

Genetic loci associated with chronic obstructive pulmonary disease overlap with loci for lung function and pulmonary fibrosis.

Hobbs BD, de Jong K, Lamontagne M, Bossé Y, Shrine N, Artigas MS, Wain LV, Hall IP, Jackson VE, Wyss AB, London SJ, North KE, Franceschini N, Strachan DP, Beaty TH, Hokanson JE, Crapo JD, Castaldi PJ, Chase RP, Bartz TM, Heckbert SR, Psaty BM, Gharib SA, Zanen P, Lammers JW, Oudkerk M, Groen HJ, Locantore N, Tal-Singer R, Rennard SI, Vestbo J, Timens W, Paré PD, Latourelle JC, Dupuis J, O'Connor GT, Wilk JB, Kim WJ, Lee MK, Oh YM, Vonk JM, de Koning HJ, Leng S, Belinsky SA, Tesfaigzi Y, Manichaikul A, Wang XQ, Rich SS, Barr RG, Sparrow D, Litonjua AA, Bakke P, Gulsvik A, Lahousse L, Brusselle GG, Stricker BH, Uitterlinden AG, Ampleford EJ, Bleecker ER, Woodruff PG, Meyers DA, Qiao D, Lomas DA, Yim JJ, Kim DK, Hawrylkiewicz I, Sliwinski P, Hardin M, Fingerlin TE, Schwartz DA, Postma DS, MacNee W, Tobin MD, Silverman EK, Boezen HM, Cho MH; COPDGene Investigators; ECLIPSE Investigators; LifeLines Investigators; SPIROMICS Research Group; International COPD Genetics Network Investigators; UK BiLEVE Investigators; International COPD Genetics Consortium.

Nat Genet. 2017 Mar;49(3):426-432. doi: 10.1038/ng.3752. Epub 2017 Feb 6.

50.

The impact of overdiagnosis on the selection of efficient lung cancer screening strategies.

Han SS, Ten Haaf K, Hazelton WD, Munshi VN, Jeon J, Erdogan SA, Johanson C, McMahon PM, Meza R, Kong CY, Feuer EJ, de Koning HJ, Plevritis SK.

Int J Cancer. 2017 Jun 1;140(11):2436-2443. doi: 10.1002/ijc.30602.

Supplemental Content

Loading ...
Support Center